Spinal cord injury (SCI) can have devastating, life-changing consequences on individuals who suffer from it. Currently, there is no cure for SCI and treatment options are limited. However, researchers are making promising progress in developing new therapies that could potentially repair damage to the spinal cord and restore lost functions.
Cell Therapies
One of the most explored approaches for SCI repair involves the transplantation of cells into the injured spinal cord site. The goal is for the cells to integrate into the host tissue and facilitate repair through multiple mechanisms such as growing new axons, reducing scar formation, and releasing neurotrophic factors.
Coherent Market Insights discusses some of the most innovative therapeutics currently under investigation for SCI in Spinal Cord Injury Therapeutics Market.
Stem Cell Therapies
Mesenchymal stem cells (MSCs) derived from bone marrow have shown potential in preclinical studies for promoting axon regrowth and reducing inflammation after SCI. In 2021, a phase I/IIa clinical trial was launched in China to evaluate the safety and efficacy of autologous bone marrow MSC transplantation in SCI patients (clinicaltrials.gov). Researchers are also investigating the use of other stem cell types like olfactory ensheathing cells which aid in nerve regeneration.
Schwann Cell Therapies
Schwann cells, the glial cells of the peripheral nervous system, play a key role in nerve repair. Grafting Schwann cells directly into the injured spinal cord site has been found to support axon regeneration and remyelination in animal models. In 2016, the first clinical trial testing human Schwann cell transplantation for SCI was initiated (clinicaltrials.gov). Preliminary results indicate the therapy was well tolerated and led to some motor improvement in patients.
Olfactory Ensheathing Cell Therapies
Olfactory ensheathing cells (OECs) from the olfactory system facilitate nerve regeneration in the nose and show similar properties to Schwann cells. Preclinical research shows OEC transplants help sprouting of axons beyond the lesion site. A few small phase I/II clinical trials so far have observed some functional benefits with OEC transplantation in SCI patients. Larger late phase studies are still needed.
Biomaterials and Scaffolds
Three-dimensional biomaterials and scaffolds are being developed to bridge the injury gap, guide regenerating axons, and deliver supportive cells or molecules. For example, agarose-collagen scaffolds seeded with Schwann cells were found to improve hindlimb function in rat SCI models. Scaffolds that degrade over time as the tissue heals hold promise. Some biomaterial approaches are now entering clinical testing.
Neurotrophic Factors
Administering neurotrophic factors, the proteins that nourish neurons, is another strategy under active investigation. Factors like glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and ciliary neurotrophic factor (CNTF) have shown capacity to promote axonal growth and improve functional recovery after SCI in animal research. Advancing these to human studies could yield new treatment options.
Combination Therapies
Given the complexity of SCI, a single therapy is unlikely to be sufficient. Researchers are exploring combining cell transplantation with biomaterials, growth factors, immunomodulators, and other aids to nerve regeneration for a synergistic effect. For instance, delivering neurotrophic factors via polymers or cellular carriers could maximize their therapeutic benefits in SCI. Combinatorial approaches hold promise but require further preclinical optimization.
Market Outlook
While significant progress has been made, there remain key challenges to bringing new SCI therapeutics to market approval and routine clinical use. Extensive research on larger animal models that more closely mimic human physiopathology will be critical to demonstrate efficacy, safety and predict clinical translation outcomes. Careful planning and execution of rigorous clinical trials will be indispensable. Government support for SCI research and streamlining of regulatory pathways could help expedite development. Though the landscape is evolving, the global SCI therapeutics market currently lacks approved pharmacologic treatments. As combination cell and drug therapies prove effective and costs of production are optimized, market adoption is anticipated to steadily rise. For more in-depth market analysis, please refer to Coherent Market Insights report on the spinal cord injury treatment market. North America currently dominates but Asia-Pacific regions like China are increasingly contributing to clinical research efforts, pointing to future growth opportunities. With continued scientific advances, novel SCI therapeutics hold promise to transform prognosis and quality of life for patients worldwide.
